title: Deal watch: Alcon invests in first non-surgical therapy for common eye disorder.
authors.forename: Sarah
authors.initials: S
authors.lastname: Crunkhorn
mesh_terms: D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D005128:Eye Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005341:Fibrinolysin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000267:Tissue Adhesions / Q000473:pathology; D014822:Vitreous Body / Q000473:pathology*; D020255:Vitreous Detachment / Q000150:complications*
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin